Defence Therapeutics, a biotechnology company, is expanding its radiopharmaceutical development program to include both alpha and beta-emitting radioisotopes. This move aims to broaden the capabilities of its proprietary Accum® technology, which is designed to improve the delivery of radioactive drugs into cancer cells. The company will compare the effectiveness of different isotopes like Actinium-225 and Lutetium-177 to develop new and improved cancer therapies.
More Markets, a lending protocol on Flow EVM, was exploited resulting in the loss of about 15.5 million WFLOW tokens, valued at roughly $9.3 million. The attack involved the use of an Ankr bonded liquid staking token (LST) combined with the protocol'...
Billionaire Dan Loeb's Third Point LLC has strategically invested over $300 million in four former cryptocurrency mining companies—Hut 8, Riot Platforms, Core Scientific, and Applied Digital—that are pivoting to AI infrastructure. These companies hav...
Dogecoin (DOGE) retreated about 14% from its August high of $0.100 to around $0.086, entering a consolidation phase after a strong surge. Despite this pullback, DOGE still shows a 25% gain for August, poised for its best monthly performance in 2026. ...
Nvidia is expected to see a 70% revenue growth by fiscal year 2028, fueled by strong demand for AI chips and expanding partnerships, including with SpaceX. The company's growth is diversifying beyond traditional hyperscalers into AI cloud ecosystems,...
GAC telah meluncurkan SUV hibrida andalannya, GAC S7, di Kazakhstan. Model ini dirakit secara lokal melalui kemitraan dengan ALLUR Group, menandai pergeseran GAC dari model ekspor murni ke produksi, penjualan, dan layanan yang terlokalisasi di Kazakh...
